Short-Term Effects of Ticagrelor and Clopidogrel on Inflammatory Factor Levels of Diabetic Patients Complicated with non-ST-elevation Acute Coronary Syndromes after Early Percutaneous Coronary Intervention
YOU San-li, WANG Zhao
Brain Hospital of Hunan Province,Changsha Hunan,410007
Abstract： Objective To observe the short-term effects of ticagrelor and clopidogrel on the Inflammatory factor levels of diabetic patients complicated with non-ST-elevation acute coronary syndromes (NSTE-ACS) after early percutaneous coronary intervention (PCI). Methods A total of 117 cases of type II diabetic mellitus patients (T2DM) with NSTE-ACS who were hospitalized and underwent early PCI in Hunan Province's Neuro Hospital from September 2015 to February 2017 were incorporated into our study. According to the prescription of antiplatelet drug administration, the patients were divided into two groups: clopidogrel group(n=72)and ticagrelor group(n=45). Patients in the two groups were given conventional treatment with 300mg of aspirin before PCI followed by 100mg each day after PCI. In addition, clopidogrel group was given 300mgclopidogrel before PCI followed by 75mg per day administered once a day.The ticagrelor group was given 180mg ticagrelor before PCI followed by 90mg per day administered twice a day. The levels of high sensitive C reactive protein(hs-CRP), interleukin-6(IL-6),interleukin-1β ( IL-1β),and soluble CD40 ligand ( sCD40L) were detected before operationand 6h,24h,3d,7d post operation. Results The levels of hs-CRP,IL-6,IL-1β,and sCD40L in the two groups were not significantly different before PCI operation(P>0.05); 6h post operation ,the levels of hs-CRP, IL-6, IL-1β , and sCD40L were higher than those before operation in both groups(P<0.05).More importantly, the level changes in the ticagrelor group were lower than those in the clopidogrel group(P<0.05). Postoperative 6h,24h,3d, and 7d ,the levels of hs-CRP,IL-6,IL-1β,and sCD40L decreased(P<0.05); the decreases in the ticagrelor group were lower than those in the clopidogrel group(P<0.05). Conclusion Both ticagrelor or clopidogrel can effectively inhibit early inflammatory response of diabetic patients complicated with non-ST-elevation acute coronary syndromes after PCI.It is important to note that ticagrelor exhibits better inhibitive effects than clopidogrel.
游三丽,王照. 替格瑞洛和氯吡格雷对早期行PCI术的NSTE-ACS合并T2DM患者围术期炎症因子的影响[J]. 医学临床研究, 2017, 34(5): 853-856.
YOU San-li, WANG Zhao. Short-Term Effects of Ticagrelor and Clopidogrel on Inflammatory Factor Levels of Diabetic Patients Complicated with non-ST-elevation Acute Coronary Syndromes after Early Percutaneous Coronary Intervention. JOURNAL OF CLINICAL RESEARCH, 2017, 34(5): 853-856.
[1] Lim SY. Predictive factors of major adverse cardiac events in acute myocardial infarction patients complicated by cardiogenic shock undergoing primary percutaneous coronary intervention[J]. Circ J, 2005, 69(2): 154-158. [2] Chen YG, Xu F, Zhang Y, et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome[J].Chin Med J (Engl) ,2006,119 (1) : 32-36. [3] 姚懿,袁晋青.新型抗血小板药物普拉格雷替格瑞洛与氯吡格雷的临床对比研究进展 [J].中华临床医师杂志(电子版) ,2013, 7 (19) : 8870-8873. [4] Amsterdam EA, Wenger NK,Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2014, 64(24):e156-157. [5] American Diabetes Association. Standards of Medical Care in Diabetes 2010[J]. Diabetes Care,2010,33 (Suppl 1):S11-13. [6] Hong YJ, Jeong MH, Choi YH, et al. Plaque characteristics in culprit lesions and inflammatory status in diabetic acute coronary syndrome patients[J]. JACC,Cardiovasc Imaging,2009,2(3):339-349. [7] 谭 静,华 琦,范振兴,等.老年急性ST段抬高心肌梗死患者血清白细胞介素6水平变化与预后的相关性[J].中华老年心脑血管病杂志,2013,15(9) : 923 - 926. [8] 李拥军,丁文惠,高炜,等.白介素-1受体拮抗剂对缺血再灌注心肌的保护作用及其机制探讨[J].中华医学杂志,2004,90 (7) : 24-29. [9] 高炎,童国新,冷建杭,等.血浆白介素-1β水平对ST段抬高性急性心肌梗塞患者介入治疗术后不良心脏事件的影响[J].中华急诊医学杂志, 2009,18(8):819-825 [10] Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes(ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC)[J].Eur Heart J,2011,32 (23):2999-3054,2009. [11] Yang Y,Lewis JP,Hulot J,et al. The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19[J].Expert Opinion Drug Metab Toxicol,2015, 11(10): 1599-1617. [12] Storelli F,Daali Y,Desmeules J,et al. Pharmacogenomics of Oral Antithrombotic Drugs[J].Curr Pharm Des,2016,22(13): 1933-1949. [13] Serebruany VL. Adenosine release: a potential explanation for the benefits of ticagrelor in the Platelet inhibition and clinical outcomes trial[J]？Am Heart J, 2011, 161 (1): 1-4. [14] Thomas MR,Outteridge SN,Ajjan RA,et al. Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model[J].Arterioscler Thromb Vasc Biol,2015,35(12): 2562-2570. [15] Tunjungputri RN, Riksen N, Rongen G, et al. Differential effects of platelets and platelet inhibition by ticagrelor on TLR2-and TLR4-mediated inflammatory responses[J].Thromb Haemost, 2015,113(5): 1035-1045.
2017, Vol. 34 
